CAREMORE

Cancer Responsiveness Monitoring based on Resistance mutations in CTCs

Coordinatore	OLINK AB    more  Organization address address: UPPSALA SCIENCE PARK city: UPPSALA postcode: 751 83 contact info Titolo: Dr. Nome: Fredrik Cognome: Hjelm Email: send email Telefono: 46184443982
Nazionalità Coordinatore	Sweden [SE]
Totale costo	7˙389˙897 €
EC contributo	5˙127˙632 €
Programma	FP7-HEALTH Specific Programme "Cooperation": Health
Code Call	FP7-HEALTH-2013-INNOVATION-2
Funding Scheme	CP-FP
Anno di inizio	2013
Periodo (anno-mese-giorno)	2013-09-01   -   2016-08-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	OLINK AB  Organization address address: UPPSALA SCIENCE PARK city: UPPSALA postcode: 751 83 contact info Titolo: Dr. Nome: Fredrik Cognome: Hjelm Email: send email Telefono: 46184443982	SE (UPPSALA)	coordinator	1˙164˙000.00
2	CYTOTRACK APS  Organization address address: GAMMEL LUNDTOFTEVEJ 1D city: LYNGBY postcode: 2800 contact info Titolo: Dr. Nome: Tom Hede Cognome: Markussen Email: send email Telefono: +45 70 27 42 00 Fax: +45 70275200	DK (LYNGBY)	participant	1˙617˙600.00
3	ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM  Organization address address: 's Gravendijkwal 230 city: ROTTERDAM postcode: 3015CE contact info Titolo: Mr. Nome: Raymond Cognome: Castelijns Email: send email Telefono: +31 107030572	NL (ROTTERDAM)	participant	1˙507˙852.00
4	PHILIPS ELECTRONICS NEDERLAND B.V.  Organization address address: Boschdijk 525 city: EINDHOVEN postcode: 5621JG contact info Titolo: Mr. Nome: Patrick Cognome: Keur Email: send email Telefono: +31 402740361	NL (EINDHOVEN)	participant	737˙980.00
5	STOCKHOLMS UNIVERSITET  Organization address address: Universitetsvaegen 10 city: STOCKHOLM postcode: 10691 contact info Titolo: Ms. Nome: Ann Cognome: Nielsen Email: send email Telefono: 468162594	SE (STOCKHOLM)	participant	100˙200.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Today's treatment of metastatic breast cancer is guided by characterisation of the primary tumour while 90% of deaths due to breast cancer occur as a consequence of metastases. Given important differences in molecular characteristics between metastases and primary tumour tissue, characterization of metastatic tumours instead of the primary tumour may provide better treatment guidance for patients with metastatic disease. Metastatic tumours are however difficult to assess using currently available techniques. We propose to clinically validate molecular methods and develop a clinically validated system for characterization of circulating tumour cells, used as proxies for the metastatic tumour, to guide treatment decisions in women with metastatic breast cancer. Two unique methods will be combined, single cell molecular characterization and improved circulating tumour cell sampling and identification, provided by the participating SMEs. Together with leading academic scientists and one industrial partner, the consortium is ideally suited to evaluate the clinical utility of the proposed methods and to validate the methods in order to reach the final development stage before the product will be introduced to the market, which constitutes a significant commercial potential for the SME-partners in the project.'